Generic placeholder image

Current Molecular Medicine

Author(s): Ya-Hui Huang*, Chau-Ting Yeh*, Chao-Wei Hsu and Yang-Hsiang Lin

DOI: 10.2174/1566524022666220510220533

DownloadDownload PDF Flyer Cite As
Reduction of ACE2 Serum Concentrations by Telbivudine in Chronic Hepatitis B Patients

Page: [420 - 424] Pages: 5

  • * (Excluding Mailing and Handling)

Abstract

Background: Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has wreaked havoc worldwide since December 2019. Currently, no effective medical treatments have been approved. As the epidemic continues to spread, SARS-CoV-2 mutants emerge, some of which become more infectious with increasing vaccine resistance. The main route for SARS-CoV-2 to enter the host cells is by binding its spike protein to the host receptor, angiotensin-converting enzyme 2 (ACE2). Besides the membrane-bound form of ACE2, the soluble form of ACE2 (sACE2) can also bind SARS-CoV-2 for viral endocytosis.

Objective: Previously, we found that telbivudine reduced the concentrations of ACE1 in blood. Therefore, we speculated that this drug might also reduce the concentrations of sACE2.

Methods: In this retrospective study, serum samples from 39 hepatitis B patients receiving telbivudine were collected and examined for sACE2 concentrations using an ELISA kit..

Results: It was found that the serum concentrations of sACE2 were significantly declined in chronic hepatitis B patients treated with telbivudine.

Conclusion: Telbivudine treatment reduced sACE2 concentrations, which could potentially reduce the infection risk of SARS-CoV-2.

Keywords: Coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, angiotensin-converting enzyme, telbivudine, hepatitis B virus, serum, SARS-CoV-2, ACE2.

[1]
Stadler K, Rappuoli R. SARS: Understanding the virus and development of rational therapy. Curr Mol Med 2005; 5(7): 677-97.
[http://dx.doi.org/10.2174/156652405774641124] [PMID: 16305493]
[2]
Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis 2020; 20(9): e238-44.
[http://dx.doi.org/10.1016/S1473-3099(20)30484-9] [PMID: 32628905]
[3]
Sun J, He WT, Wang L, et al. COVID-19: Epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med 2020; 26(5): 483-95.
[http://dx.doi.org/10.1016/j.molmed.2020.02.008] [PMID: 32359479]
[4]
Centers for disease control and prevention. Available from:cdc.gov/coronavirus/2019-ncov/variants/variant-info.html (Accessed Apr 21, 2022).
[5]
Scialo F, Daniele A, Amato F, et al. ACE2: The major cell entry receptor for SARS-CoV-2. Lung 2020; 198(6): 867-77.
[http://dx.doi.org/10.1007/s00408-020-00408-4] [PMID: 33170317]
[6]
Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc 2020; 9(7): e016219.
[http://dx.doi.org/10.1161/JAHA.120.016219] [PMID: 32233755]
[7]
Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: Angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014; 16(3): 420.
[http://dx.doi.org/10.1007/s11906-014-0420-5] [PMID: 24510672]
[8]
Yalcin HC, Sukumaran V, Al-Ruweidi MKAA, Shurbaji S. Do changes in ACE-2 expression affect SARS-CoV-2 virulence and related complications: A closer look into membrane-bound and soluble forms. Int J Mol Sci 2021; 22(13): 6703.
[http://dx.doi.org/10.3390/ijms22136703] [PMID: 34201415]
[9]
Yeung ML, Teng JLL, Jia L, et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell 2021; 184(8): 2212-2228.e12.
[http://dx.doi.org/10.1016/j.cell.2021.02.053] [PMID: 33713620]
[10]
Ou J, Zhang Y, Wang Y, et al. ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants. Signal Transduct Target Ther 2022; 7(1): 43.
[http://dx.doi.org/10.1038/s41392-022-00913-3] [PMID: 35140198]
[11]
Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007; 29(12): 2635-53.
[http://dx.doi.org/10.1016/j.clinthera.2007.12.032] [PMID: 18201580]
[12]
Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014; 146(1): 138-146.e5.
[http://dx.doi.org/10.1053/j.gastro.2013.09.031] [PMID: 24067879]
[13]
Park J, Jung KS, Lee HW, et al. Effects of entecavir and tenofovir on renal function in patients with hepatitis B virus-related compensated and decompensated cirrhosis. Gut Liver 2017; 11(6): 828-34.
[http://dx.doi.org/10.5009/gnl16484] [PMID: 28651305]
[14]
Liang KH, Chen YC, Hsu CW, Chang ML, Yeh CT. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates. Hepat Mon 2014; 14(1): e15074.
[http://dx.doi.org/10.5812/hepatmon.15074] [PMID: 24596580]
[15]
Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing 2022.
[16]
Glasgow A, Glasgow J, Limonta D, et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci USA 2020; 117(45): 28046-55.
[http://dx.doi.org/10.1073/pnas.2016093117] [PMID: 33093202]
[17]
Zhu ZL, Qiu XD, Wu S, et al. Blocking effect of demethylzeylasteral on the interaction between human ACE2 protein and SARS-CoV-2 RBD protein discovered using SPR technology. Molecules 2020; 26(1): 57.
[http://dx.doi.org/10.3390/molecules26010057] [PMID: 33374387]
[18]
Karoyan P, Vieillard V, Gómez-Morales L, et al. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Commun Biol 2021; 4(1): 197.
[http://dx.doi.org/10.1038/s42003-021-01736-8] [PMID: 33580154]
[19]
Rahman MR, Banik A, Chowdhury IM, Sajib EH, Sarkar S. Identification of potential antivirals against SARS-CoV-2 using virtual screening method. Inform Med Unlocked 2021; 23: 100531.
[http://dx.doi.org/10.1016/j.imu.2021.100531] [PMID: 33594342]
[20]
Maurya SK, Maurya AK, Mishra N, Siddique HR. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2. J Recept Signal Transduct Res 2020; 40(6): 605-12.
[http://dx.doi.org/10.1080/10799893.2020.1772298] [PMID: 32476594]
[21]
Elzupir AO. Molecular docking and dynamics investigations for identifying potential inhibitors of the 3-chymotrypsin-like protease of SARS-CoV-2: Repurposing of approved pyrimidonic pharmaceuticals for COVID-19 treatment. Molecules 2021; 26(24): 7458.
[http://dx.doi.org/10.3390/molecules26247458] [PMID: 34946540]
[22]
Min JS, Kwon S, Jin YH. SARS-CoV-2 RdRp inhibitors selected from a cell-based SARS-CoV-2 RdRp activity assay system. Biomedicines 2021; 9(8): 996.
[http://dx.doi.org/10.3390/biomedicines9080996] [PMID: 34440200]